C

Citius Pharmaceuticals
D

CTXR

1.67000
USD
-0.03
(-1.47%)
مغلق
حجم التداول
9,443
الربح لكل سهم
-4
العائد الربحي
-
P/E
-0
حجم السوق
18,661,358
أصول ذات صلة
A
ATRA
-0.440
(-3.61%)
11.760 USD
A
AUPH
-0.13500
(-1.49%)
8.93000 USD
A
AVXL
-0.635
(-4.98%)
12.125 USD
B
BCRX
0.00000
(0.00%)
8.55500 USD
B
BTAI
0.07000
(4.07%)
1.79000 USD
C
CRBP
0.18000
(2.00%)
9.17000 USD
K
KPTI
-0.10000
(-2.24%)
4.36000 USD
O
OCGN
-0.02000
(-1.79%)
1.09500 USD
P
PLX
-0.04000
(-2.57%)
1.51500 USD
المزيد
الأخبار المقالات

العنوان: Citius Pharmaceuticals Inc

القطاع: Healthcare
الصناعة: Biotechnology
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.